The device for endotoxic septic shock was first approved in Europe more than 20 years ago, in 1994, by Toray Industries.

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

Newron has randomised the first participants in its ENIGMA-TRS 1 Phase III programme of evenamide for treatment-resistant ...